{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:51:26Z","timestamp":1793055086695,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA256741"],"award-info":[{"award-number":["R01CA256741"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by adenosine deaminases acting on RNA (ADARs), is a widespread modification in metazoans. Cumulative evidence has revealed the altered A-to-I editing profiles in cancers, but the underlying mechanism remains unclear. Here, we discover the well-known histone lysine methyltransferase enhancer of zeste homologue 2 (EZH2) as an unexplored ADAR interactor and editing regulator in prostate cancer (PCa). Through competing with interleukin enhancer binding factor 2 (ILF2) for ADAR1 binding, EZH2 reshapes the substrate selectivity of ADAR1 and thus exhibits a bidirectional role in editing regulation. Moreover, EZH2 depletion induces the translational repression of transportin-1 (TRN1), which further results in the accumulation of cytoplasmic ADAR1p110 isoform to protect many oncogenic transcripts from degradation. Consistently, depletion of ADAR1 dramatically enhances the sensitivity of cancer cells and tumors to EZH2 selective degraders. Collectively, our study sheds new light on a link between two layers of epigenetic regulations at histone modification and RNA editing levels, demonstrates a previously uncharacterized role of EZH2 in RNA editing and mRNA stability independently of its lysine methyltransferase activity, and reveals the significance of EZH2-ADAR1 cascade in governing RNA editing and mRNA stability, which may provide additional perspectives for the advancement of EZH2-targeting cancer therapies.<\/jats:p>","DOI":"10.1038\/s41467-026-71207-3","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:25:07Z","timestamp":1774484707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-7249","authenticated-orcid":false,"given":"Yang","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6846-6884","authenticated-orcid":false,"given":"Yanqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-7890","authenticated-orcid":false,"given":"Xufen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-4201","authenticated-orcid":false,"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5830-7608","authenticated-orcid":false,"given":"Chaehyun","family":"Yum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3476-8937","authenticated-orcid":false,"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3480","authenticated-orcid":false,"given":"Yuanyuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4133-0634","authenticated-orcid":false,"given":"Aileen","family":"Szczepanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaqia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Fazli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangchuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-335X","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-1569","authenticated-orcid":false,"given":"Xiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-0896","authenticated-orcid":false,"given":"Ping","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0699-1899","authenticated-orcid":false,"given":"Edward M.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9106-9016","authenticated-orcid":false,"given":"Heather A.","family":"Hundley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1768-0674","authenticated-orcid":false,"given":"Hengyao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-3415","authenticated-orcid":false,"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-0747","authenticated-orcid":false,"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9200-5068","authenticated-orcid":false,"given":"Jinjun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3115-3371","authenticated-orcid":false,"given":"Xuesen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-2571","authenticated-orcid":false,"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-4357","authenticated-orcid":false,"given":"Kaifu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-3681","authenticated-orcid":false,"given":"Qi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"71207_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2012-13-12-252","volume":"13","author":"YA Savva","year":"2012","unstructured":"Savva, Y. A., Rieder, L. E. & Reenan, R. A. The ADAR protein family. Genome Biol. 13, 252 (2012).","journal-title":"Genome Biol."},{"key":"71207_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrm.2015.4","volume":"17","author":"K Nishikura","year":"2016","unstructured":"Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat. Rev. Mol. Cell Biol. 17, 83\u201396 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"71207_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.tig.2019.09.004","volume":"35","author":"M Jain","year":"2019","unstructured":"Jain, M., Jantsch, M. F. & Licht, K. The Editor\u2019s I on Disease Development. Trends Genet. 35, 903\u2013913 (2019).","journal-title":"Trends Genet."},{"key":"71207_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature24041","volume":"550","author":"MH Tan","year":"2017","unstructured":"Tan, M. H. et al. Dynamic landscape and regulation of RNA editing in mammals. Nature 550, 249\u2013254 (2017).","journal-title":"Nature"},{"key":"71207_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.canlet.2017.09.036","volume":"411","author":"C Wang","year":"2017","unstructured":"Wang, C. et al. Mechanisms and implications of ADAR-mediated RNA editing in cancer. Cancer Lett. 411, 27\u201334 (2017).","journal-title":"Cancer Lett."},{"key":"71207_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1347-3","volume":"18","author":"CR Walkley","year":"2017","unstructured":"Walkley, C. R. & Li, J. B. Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs. Genome Biol. 18, 205 (2017).","journal-title":"Genome Biol."},{"key":"71207_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7355","volume":"6","author":"JH Bahn","year":"2015","unstructured":"Bahn, J. H. et al. Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways. Nat. Commun. 6, 6355 (2015).","journal-title":"Nat. Commun."},{"key":"71207_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cell.2013.03.024","volume":"153","author":"H Ota","year":"2013","unstructured":"Ota, H. et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 153, 575\u201389 (2013).","journal-title":"Cell"},{"key":"71207_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.celrep.2013.10.002","volume":"5","author":"IX Wang","year":"2013","unstructured":"Wang, I. X. et al. ADAR regulates RNA editing, transcript stability, and gene expression. Cell Rep. 5, 849\u201360 (2013).","journal-title":"Cell Rep."},{"key":"71207_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nsmb.3403","volume":"24","author":"M Sakurai","year":"2017","unstructured":"Sakurai, M. et al. ADAR1 controls apoptosis of stressed cells by inhibiting Staufen1-mediated mRNA decay. Nat. Struct. Mol. Biol. 24, 534\u2013543 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"71207_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccell.2015.08.013","volume":"28","author":"L Han","year":"2015","unstructured":"Han, L. et al. The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell 28, 515\u2013528 (2015).","journal-title":"Cancer Cell"},{"key":"71207_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.celrep.2015.08.080","volume":"13","author":"N Paz-Yaacov","year":"2015","unstructured":"Paz-Yaacov, N. et al. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 13, 267\u201376 (2015).","journal-title":"Cell Rep."},{"key":"71207_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ccell.2018.03.026","volume":"33","author":"X Peng","year":"2018","unstructured":"Peng, X. et al. A-to-I RNA editing contributes to proteomic diversity in cancer. Cancer Cell 33, 817\u2013828.e7 (2018).","journal-title":"Cancer Cell"},{"key":"71207_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gde.2017.10.009","volume":"48","author":"X Xu","year":"2018","unstructured":"Xu, X., Wang, Y. & Liang, H. The role of A-to-I RNA editing in cancer development. Curr. Opin. Genet Dev. 48, 51\u201356 (2018).","journal-title":"Curr. Opin. Genet Dev."},{"key":"71207_CR15","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1101\/gr.6493107","volume":"17","author":"N Paz","year":"2007","unstructured":"Paz, N. et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 17, 1586\u201395 (2007).","journal-title":"Genome Res."},{"key":"71207_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep23226","volume":"6","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Altered RNA editing in 3\u2019 UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. Sci. Rep. 6, 23226 (2016).","journal-title":"Sci. Rep."},{"key":"71207_CR17","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1073\/pnas.1507882112","volume":"112","author":"A Salameh","year":"2015","unstructured":"Salameh, A. et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc. Natl. Acad. Sci. USA 112, 8403\u20138 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71207_CR18","doi-asserted-by":"publisher","first-page":"29938","DOI":"10.1074\/jbc.M800534200","volume":"283","author":"HD Martinez","year":"2008","unstructured":"Martinez, H. D. et al. RNA editing of androgen receptor gene transcripts in prostate cancer cells. J. Biol. Chem. 283, 29938\u201349 (2008).","journal-title":"J. Biol. Chem."},{"key":"71207_CR19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039\u201343 (2002).","journal-title":"Science"},{"key":"71207_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343\u20139 (2011).","journal-title":"Nature"},{"key":"71207_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624\u20139 (2002).","journal-title":"Nature"},{"key":"71207_CR22","doi-asserted-by":"crossref","unstructured":"Park, S.H. et al. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene 40, 5788\u20135798 (2021).","DOI":"10.1038\/s41388-021-01982-4"},{"key":"71207_CR23","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","volume":"25","author":"J Kim","year":"2018","unstructured":"Kim, J. et al. Polycomb- and methylation-independent roles of ezh2 as a transcription activator. Cell Rep. 25, 2808\u20132820 e4 (2018).","journal-title":"Cell Rep."},{"key":"71207_CR24","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/s41388-020-1332-2","volume":"39","author":"AE Koyen","year":"2020","unstructured":"Koyen, A. E. et al. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene 39, 4798\u20134813 (2020).","journal-title":"Oncogene"},{"key":"71207_CR25","doi-asserted-by":"crossref","unstructured":"Zhao, Y. et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 38, EMBJ201899599 (2019).","DOI":"10.15252\/embj.201899599"},{"key":"71207_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","volume":"24","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat. Cell Biol. 24, 384\u2013399 (2022).","journal-title":"Nat. Cell Biol."},{"key":"71207_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41556-021-00653-6","volume":"23","author":"Y Yi","year":"2021","unstructured":"Yi, Y. et al. A PRC2-independent function for EZH2 in regulating rRNA 2\u2019-O methylation and IRES-dependent translation. Nat. Cell Biol. 23, 341\u2013354 (2021).","journal-title":"Nat. Cell Biol."},{"key":"71207_CR28","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41388-022-02208-x","volume":"41","author":"Y Yi","year":"2022","unstructured":"Yi, Y. et al. Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer. Oncogene 41, 1610\u20131621 (2022).","journal-title":"Oncogene"},{"key":"71207_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4127","volume":"5","author":"Q Cao","year":"2014","unstructured":"Cao, Q. et al. The central role of EED in the orchestration of polycomb group complexes. Nat. Commun. 5, 3127 (2014).","journal-title":"Nat. Commun."},{"key":"71207_CR30","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-16-2054","volume":"23","author":"HM Lam","year":"2017","unstructured":"Lam, H. M. et al. Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin. Cancer Res. 23, 2301\u20132312 (2017).","journal-title":"Clin. Cancer Res."},{"key":"71207_CR31","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/nsmb.2679","volume":"20","author":"C Davidovich","year":"2013","unstructured":"Davidovich, C. et al. Promiscuous RNA binding by Polycomb repressive complex 2. Nat. Struct. Mol. Biol. 20, 1250\u20137 (2013).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"71207_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 162, 454 (2015).","journal-title":"Cell"},{"key":"71207_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0370-3","volume":"13","author":"LA Crews","year":"2015","unstructured":"Crews, L. A. et al. An RNA editing fingerprint of cancer stem cell reprogramming. J. Transl. Med. 13, 52 (2015).","journal-title":"J. Transl. Med."},{"key":"71207_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan, L. et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark. Res. 6, 10 (2018).","journal-title":"Biomark. Res."},{"key":"71207_CR35","doi-asserted-by":"publisher","first-page":"16054","DOI":"10.1074\/jbc.M611392200","volume":"282","author":"L Valente","year":"2007","unstructured":"Valente, L. & Nishikura, K. RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions. J. Biol. Chem. 282, 16054\u201361 (2007).","journal-title":"J. Biol. Chem."},{"key":"71207_CR36","doi-asserted-by":"publisher","first-page":"107656","DOI":"10.1016\/j.celrep.2020.107656","volume":"31","author":"EC Freund","year":"2020","unstructured":"Freund, E. C. et al. Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing. Cell Rep. 31, 107656 (2020).","journal-title":"Cell Rep."},{"key":"71207_CR37","doi-asserted-by":"crossref","unstructured":"Licht, K. & Jantsch, M.F. The other face of an editor: ADAR1 functions in editing-independent ways. Bioessays 39, 1700129 (2017).","DOI":"10.1002\/bies.201700129"},{"key":"71207_CR38","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1128\/MCB.01519-08","volume":"29","author":"J Fritz","year":"2009","unstructured":"Fritz, J. et al. RNA-regulated interaction of transportin-1 and exportin-5 with the double-stranded RNA-binding domain regulates nucleocytoplasmic shuttling of ADAR1. Mol. Cell Biol. 29, 1487\u201397 (2009).","journal-title":"Mol. Cell Biol."},{"key":"71207_CR39","doi-asserted-by":"publisher","first-page":"e79288","DOI":"10.1371\/journal.pone.0079288","volume":"8","author":"JJ Hong","year":"2013","unstructured":"Hong, J. J. et al. Viral IRES prediction system - a web server for prediction of the IRES secondary structure in silico. PLoS ONE 8, e79288 (2013).","journal-title":"PLoS ONE"},{"key":"71207_CR40","doi-asserted-by":"publisher","first-page":"101042831880301","DOI":"10.1177\/1010428318803011","volume":"40","author":"RC Pimenta","year":"2018","unstructured":"Pimenta, R. C. et al. MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line. Tumour Biol. 40, 1010428318803011 (2018).","journal-title":"Tumour Biol."},{"key":"71207_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0941-2","volume":"18","author":"Y Yin","year":"2019","unstructured":"Yin, Y. et al. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421\/ATM pathway. Mol. Cancer 18, 11 (2019).","journal-title":"Mol. Cancer"},{"key":"71207_CR42","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/1535-7163.MCT-21-0958","volume":"21","author":"I Garmendia","year":"2022","unstructured":"Garmendia, I. et al. YES1: a novel therapeutic target and biomarker in cancer. Mol. Cancer Ther. 21, 1371\u20131380 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"71207_CR43","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1210\/me.2008-0280","volume":"23","author":"DJ van de Wijngaart","year":"2009","unstructured":"van de Wijngaart, D. J. et al. Functional screening of FxxLF-like peptide motifs identifies SMARCD1\/BAF60a as an androgen receptor cofactor that modulates TMPRSS2 expression. Mol. Endocrinol. 23, 1776\u201386 (2009).","journal-title":"Mol. Endocrinol."},{"key":"71207_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan, R., Du, W. & Guo, W. EZH2: a novel target for cancer treatment. J. Hematol. Oncol. 13, 104 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"71207_CR45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/acsptsci.2c00100","volume":"5","author":"B Dale","year":"2022","unstructured":"Dale, B. et al. Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of zeste homolog 2. ACS Pharm. Transl. Sci. 5, 491\u2013507 (2022).","journal-title":"ACS Pharm. Transl. Sci."},{"key":"71207_CR46","doi-asserted-by":"publisher","first-page":"7953","DOI":"10.1093\/nar\/gky396","volume":"46","author":"H Hong","year":"2018","unstructured":"Hong, H. et al. Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancer. Nucleic Acids Res. 46, 7953\u20137969 (2018).","journal-title":"Nucleic Acids Res."},{"key":"71207_CR47","doi-asserted-by":"publisher","first-page":"eaba5136","DOI":"10.1126\/sciadv.aba5136","volume":"6","author":"J Han","year":"2020","unstructured":"Han, J. et al. Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progression. Sci. Adv. 6, eaba5136 (2020).","journal-title":"Sci. Adv."},{"key":"71207_CR48","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1093\/nar\/gky615","volume":"46","author":"R Shanmugam","year":"2018","unstructured":"Shanmugam, R. et al. SRSF9 selectively represses ADAR2-mediated editing of brain-specific sites in primates. Nucleic Acids Res. 46, 7379\u20137395 (2018).","journal-title":"Nucleic Acids Res."},{"key":"71207_CR49","doi-asserted-by":"publisher","first-page":"112532","DOI":"10.1016\/j.biopha.2021.112532","volume":"146","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh, M. D. A. et al. EZH2 as a new therapeutic target in brain tumors: molecular landscape, therapeutic targeting and future prospects. Biomed. Pharmacother. 146, 112532 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"71207_CR50","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41591-018-0116-5","volume":"24","author":"I Canadas","year":"2018","unstructured":"Canadas, I. et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat. Med. 24, 1143\u20131150 (2018).","journal-title":"Nat. Med."},{"key":"71207_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.celrep.2019.08.105","volume":"29","author":"A Hirukawa","year":"2019","unstructured":"Hirukawa, A. et al. Reduction of Global H3K27me(3) enhances HER2\/ErbB2 targeted therapy. Cell Rep. 29, 249\u2013257.e8 (2019).","journal-title":"Cell Rep."},{"key":"71207_CR52","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","volume":"2","author":"KL Morel","year":"2021","unstructured":"Morel, K. L. et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat. Cancer 2, 444\u2013456 (2021).","journal-title":"Nat. Cancer"},{"key":"71207_CR53","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1101\/gr.131508.111","volume":"22","author":"JC Zhao","year":"2012","unstructured":"Zhao, J. C. et al. Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res. 22, 322\u201331 (2012).","journal-title":"Genome Res."},{"key":"71207_CR54","unstructured":"Liao, Y. et al. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proc. Natl. Acad. Sci. USA 119, e2105898119 (2022)."},{"key":"71207_CR55","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","volume":"64","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2. J. Med Chem. 64, 2829\u20132848 (2021).","journal-title":"J. Med Chem."},{"key":"71207_CR56","doi-asserted-by":"publisher","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","volume":"64","author":"Y Tu","year":"2021","unstructured":"Tu, Y. et al. Design, synthesis, and evaluation of VHL-Based EZH2 degraders to enhance therapeutic activity against lymphoma. J. Med Chem. 64, 10167\u201310184 (2021).","journal-title":"J. Med Chem."},{"key":"71207_CR57","doi-asserted-by":"crossref","unstructured":"Yi, Y. et al. EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway. J. Clin. Investig. 136, e195840 (2026).","DOI":"10.1172\/JCI195840"},{"key":"71207_CR58","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1078-0432.CCR-11-1867","volume":"18","author":"V Tzelepi","year":"2012","unstructured":"Tzelepi, V. et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin. Cancer Res. 18, 666\u201377 (2012).","journal-title":"Clin. Cancer Res."},{"key":"71207_CR59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347\u201358 (2016).","journal-title":"Nat. Protoc."},{"key":"71207_CR60","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u201360 (2009).","journal-title":"Bioinformatics"},{"key":"71207_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"71207_CR62","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u20139 (2015).","journal-title":"Bioinformatics"},{"key":"71207_CR63","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/bioinformatics\/btt287","volume":"29","author":"E Picardi","year":"2013","unstructured":"Picardi, E. & Pesole, G. REDItools: high-throughput RNA editing detection made easy. Bioinformatics 29, 1813\u20134 (2013).","journal-title":"Bioinformatics"},{"key":"71207_CR64","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/s41596-019-0279-7","volume":"15","author":"C Lo Giudice","year":"2020","unstructured":"Lo Giudice, C. et al. Investigating RNA editing in deep transcriptome datasets with REDItools and REDIportal. Nat. Protoc. 15, 1098\u20131131 (2020).","journal-title":"Nat. Protoc."},{"key":"71207_CR65","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1093\/bioinformatics\/btaa066","volume":"36","author":"SS Tran","year":"2020","unstructured":"Tran, S. S., Zhou, Q. & Xiao, X. Statistical inference of differential RNA-editing sites from RNA-sequencing data by hierarchical modeling. Bioinformatics 36, 2796\u20132804 (2020).","journal-title":"Bioinformatics"},{"key":"71207_CR66","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. Low RNA stability signifies increased post-transcriptional regulation of cell identity genes. Nucleic Acids Res. 51, 6020\u20136038 (2023).","DOI":"10.1093\/nar\/gkad300"},{"key":"71207_CR67","doi-asserted-by":"crossref","unstructured":"Park, S.H. et al. Posttranslational regulation of FOXA1 by Polycomb and BUB3\/USP7 deubiquitin complex in prostate cancer. Sci Adv. 7, eabe2261 (2021).","DOI":"10.1126\/sciadv.abe2261"},{"key":"71207_CR68","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41375-021-01161-0","volume":"35","author":"JL Berg","year":"2021","unstructured":"Berg, J. L. et al. EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. Leukemia 35, 1521\u20131526 (2021).","journal-title":"Leukemia"},{"key":"71207_CR69","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1038\/onc.2016.453","volume":"36","author":"J Li","year":"2017","unstructured":"Li, J. et al. TRIM28 interacts with EZH2 and SWI\/SNF to activate genes that promote mammosphere formation. Oncogene 36, 2991\u20133001 (2017).","journal-title":"Oncogene"},{"key":"71207_CR70","doi-asserted-by":"publisher","first-page":"107115","DOI":"10.1016\/j.isci.2023.107115","volume":"26","author":"GJ Dardis","year":"2023","unstructured":"Dardis, G. J. et al. An EZH2-NF-kappaB regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer. iScience 26, 107115 (2023).","journal-title":"iScience"},{"key":"71207_CR71","doi-asserted-by":"publisher","first-page":"D94","DOI":"10.1093\/nar\/gks955","volume":"41","author":"RZ Cer","year":"2013","unstructured":"Cer, R. Z. et al. Non-B DB v2.0: a database of predicted non-B DNA-forming motifs and its associated tools. Nucleic Acids Res.41, D94\u2013D100 (2013).","journal-title":"Nucleic Acids Res."},{"key":"71207_CR72","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20139 (2009).","journal-title":"Bioinformatics"},{"key":"71207_CR73","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1093\/bioinformatics\/btx100","volume":"33","author":"P Danecek","year":"2017","unstructured":"Danecek, P. & McCarthy, S. A. BCFtools\/csq: haplotype-aware variant consequences. Bioinformatics 33, 2037\u20132039 (2017).","journal-title":"Bioinformatics"},{"key":"71207_CR74","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.1093\/nar\/gkaa305","volume":"48","author":"AA Schaffer","year":"2020","unstructured":"Schaffer, A. A. et al. The cell line A-to-I RNA editing catalogue. Nucleic Acids Res. 48, 5849\u20135858 (2020).","journal-title":"Nucleic Acids Res."},{"key":"71207_CR75","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1021\/pr500880b","volume":"13","author":"N Rauniyar","year":"2014","unstructured":"Rauniyar, N. & Yates, J. R. 3rd, Isobaric labeling-based relative quantification in shotgun proteomics. J. Proteome Res. 13, 5293\u2013309 (2014).","journal-title":"J. Proteome Res."},{"key":"71207_CR76","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-1-4939-7204-3_14","volume":"1648","author":"EL Van Nostrand","year":"2017","unstructured":"Van Nostrand, E. L. et al. Robust, cost-effective profiling of RNA-binding protein targets with single-end enhanced crosslinking and immunoprecipitation (seCLIP). Methods Mol. Biol. 1648, 177\u2013200 (2017).","journal-title":"Methods Mol. Biol."},{"key":"71207_CR77","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1093\/bioinformatics\/bts569","volume":"28","author":"PJ Uren","year":"2012","unstructured":"Uren, P. J. et al. Site identification in high-throughput RNA-protein interaction data. Bioinformatics 28, 3013\u201320 (2012).","journal-title":"Bioinformatics"},{"key":"71207_CR78","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u201389 (2010).","journal-title":"Mol. Cell"},{"key":"71207_CR79","doi-asserted-by":"publisher","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ramirez","year":"2016","unstructured":"Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160\u20135 (2016).","journal-title":"Nucleic Acids Res."},{"key":"71207_CR80","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/pros.22988","volume":"75","author":"Y Yu","year":"2015","unstructured":"Yu, Y. et al. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate 75, 1043\u201350 (2015).","journal-title":"Prostate"},{"key":"71207_CR81","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nature21373","volume":"543","author":"F Neri","year":"2017","unstructured":"Neri, F. et al. Intragenic DNA methylation prevents spurious transcription initiation. Nature 543, 72\u201377 (2017).","journal-title":"Nature"},{"key":"71207_CR82","doi-asserted-by":"publisher","first-page":"7779","DOI":"10.1073\/pnas.1505629112","volume":"112","author":"X Zhu","year":"2015","unstructured":"Zhu, X. et al. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc. Natl. Acad. Sci. USA 112, 7779\u201384 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71207_CR83","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/cr.2009.6","volume":"19","author":"J Ren","year":"2009","unstructured":"Ren, J. et al. DOG 1.0: illustrator of protein domain structures. Cell Res. 19, 271\u20133 (2009).","journal-title":"Cell Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71207-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71207-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71207-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:03:36Z","timestamp":1779149016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71207-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71207"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71207-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J. is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc., Accent Therapeutics, Inc, and Tavotek Biotherapeutics, Inc. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. A.M.C. is a co-founder and serves on the scientific advisory boards of LynxDx, Oncopia and Esanik. A.M.C. serves on the scientific advisory board of Tempus and Ascentage. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4421"}}